Navigation Links
MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
Date:2/11/2009

VALENCIA, Calif., Feb. 11 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2008 fourth quarter financial results on Tuesday, February 17, 2009.

Management of the Company will host a conference call to discuss the fourth quarter financial results, clinical progress and other Company developments at 4:00 p.m. ET on Tuesday, February 17, 2009. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in listening to the conference call live via the internet may do so by visiting the Company's website at http://www.mannkindcorp.com. The web site replay will be available for 14 days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (800) 756-2759 or (402) 998-0791.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in Phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to email alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.


'/>"/>
SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
2. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
3. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
4. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
5. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
6. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
7. MannKind to Present at the UBS Global Life Sciences Conference
8. MannKind Corporation Reports Second Quarter Financial Results
9. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
10. MannKind to Present at Upcoming Conferences
11. MannKind Corporation Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... an underwriting agreement with Rodman & Renshaw, a unit ... sole book running manager and representative of several underwriters, under ... firm commitment basis a minimum of 2,105,264 shares of ... purchase a minimum of 1,052,632 shares of common stock ...
(Date:1/23/2017)... -- Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) ... financing, raising $35 million from a syndicate including all Series ... ... Atlas Genetics io® system has been completed with the successful ... February 2016.  This new Series D equity issue will finance ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L Scientific ... healthcare industry ( http://www.gandlscientific.com ), has announced the opening of new offices in ... scientific consultants and contractors. This is the latest step in G&L’s expansion of ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, Inc. ... focused on the licensing, development and commercialization of innovative ... Best Company in North America ... the award based on the FDA approval of ... tablets), ENTYCE ® (capromorelin oral solution) and NOCITA ...
Breaking Biology Technology:
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
(Date:12/15/2016)... Germany , December 15, 2016 ... announced an agreement with NuData Security, an award-winning ... partnership will enable clients to focus on good customer experience, ... protection regulation. ... In order to provide a one-stop fraud prevention suite, ...
(Date:12/15/2016)... -- "Increase in mobile transactions is driving the growth ... is expected to grow from USD 4.03 billion in ... CAGR of 29.3% between 2016 and 2022. The market ... for smart devices, government initiatives, and increasing penetration of ... expected to grow at a high rate during the ...
Breaking Biology News(10 mins):